The Toxicity of T-DM1 in Breast Cancer Patients with Liver Metastases
Mark D. Pegram, MD, a professor of medicine at Stanford University Medical Center and the director of the Breast Cancer Program at the Stanford Cancer Institute, discusses the results of a retrospective analysis that examined the toxicity of patients with liver metastases that were enrolled in phase III studies of T-DM1 for metastatic breast cancer.
Mark D. Pegram, MD, a professor of medicine at Stanford University Medical Center and the director of the Breast Cancer Program at the Stanford Cancer Institute, discusses the results of a retrospective analysis that examined the toxicity of patients with liver metastases that were enrolled in phase III studies of T-DM1 for metastatic breast cancer.
Clinical Pearls:
- The analysis showed that patients with liver metastases or liver metastases plus elevated LFTs at baseline had the same incidence of grade 3/4 adverse events as those patients that did not have liver metastases or elevated LFTs at baseline
- The patients in those subgroups that did experience adverse events mostly experienced laboratory adverse events
- The analysis also showed that T-DM1 in the patients who had liver metastases or liver metastases plus elevated LFTs at baseline was still superior to the control-treated patients
- These results show that liver metastases is not an impediment to safe and efficacious use of T-DM1
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
